Therefore, combined targeting of the PI3K/AKT/mTOR and the Ras/MEK/ERK pathways has been proposed as an alternative approach in a range of different cancers, including multiple myeloma (MM), melanoma and prostate cancer [6, 14, 15]. The gene discussed is AKT1; the disease is prostate cancer.